Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunovant (IMVT) Other Operating Expenses (2019 - 2023)

Immunovant filings provide 3 years of Other Operating Expenses readings, the most recent being $12.5 million for Q2 2023.

  • Quarterly Other Operating Expenses changed N/A to $12.5 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $12.5 million through Mar 2024, up 25.0% year-over-year, with the annual reading at $12.5 million for FY2024, 25.0% up from the prior year.
  • Other Operating Expenses hit $12.5 million in Q2 2023 for Immunovant, up from $10.0 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $12.5 million in Q2 2023 and bottomed at -$8.9 million in Q1 2019.
  • Average Other Operating Expenses over 3 years is $4.5 million, with a median of $10.0 million recorded in 2022.